Knowledge Library

OncoWuXi Express: Efficacy of DLL3 CAR-T in SHP-77 Tumor Models

OncoWuXi Express: Evaluation of DLL3 CAR-T in SHP-77-Luc Tumor Models  Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we showcase our DLL3 CAR-T cell preparation and evaluation of their anti-tumor …Read More >

Resource Type: Article, Blog
Resource Topic: CAR-T Cell, Oncology, Tumor Models

VIEW

Combating Drug Resistance in Cancer Therapy

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. This resistance is inherent to the tumor cells themselves, as well as tied to factors within the tumor microenvironment (TME). To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of tumor resistance, WuXi Biology has …Read More >

Resource Type: Video
Resource Topic: Oncology, Tumor Models

VIEW

OncoWuXi Express: Paclitaxel-Induced Resistant Tumor Models

Introduction: OncoWuXi Express will continue to keep you informed about updates to our online tumor model database (OncoWuXi Database), as well as our recent progress in cancer and autoimmune research. In this issue, we would like to share with you the newly established paclitaxel resistant HGC27 and HCC1806 tumor models. https://onco.wuxiapptec.com Paclitaxel, known for its …Read More >

Resource Type: Article, Blog
Resource Topic: Oncology, Tumor Models

VIEW

Expanded Role of PDX Models in Anticancer Drug Development

Expanded Role of PDX Models in Anticancer Drug Development Patient-derived xenograft (PDX) models are established by implanting surgically resected patient tumor tissues into immunodeficient mice and have become a pivotal tool in preclinical cancer research due to high clinical-relevance. These models faithfully preserve the original tumor’s molecular, histopathological and pharmacological characteristics, reflecting the heterogeneity and …Read More >

Resource Type: Article, Blog
Resource Topic: Oncology, Tumor Models

VIEW

Unveiling Mechanisms of CDK4-CDK6 Inhibitor Resistance in Breast Cancer Models

Cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits form complexes that are essential for driving abnormal growth processes in cancer cells.  Although CDK4/6 inhibitors have shown promising results in the clinic, acquired resistance to these therapies is frequently observed. The successful development of next generation therapeutics necessitates a better understanding of the mechanisms underlying this …Read More >

Resource Type: Latest Science, Poster
Resource Topic: Oncology, Tumor Models

VIEW

Targeted Protein Degradation of Mutant ER-alpha

Estrogen receptor α (ERα) is considered the main driver in more than 70% of all breast cancers, making this transcription factor an important drug target.  Activating point mutations in the ERα gene, especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies, and there is an urgent need to develop new strategies …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Oncology, Targeted Protein Degradation, Tumor Models

VIEW

siRNA Efficacy in a Xenograft Tumor Model

Protein kinase N3 (PKN3) is a serine/threonine kinase implicated in tumor progression across multiple cancer types.  PKN3 mRNA is almost undetectable in normal adult tissues but is upregulated in various cancer cells, indicating that siRNA may be a promising approach to inhibit tumor growth by reducing the expression of PKN3.  WuXi AppTec scientists established different siPKN3 molecules and evaluated …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Oligonucleotides, Oncology, Tumor Models

VIEW

Paclitaxel-Resistant Tumor Models

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce the influence of this chemotherapeutic agent. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Oncology, Tumor Models

VIEW

NK Cell Humanized Tumor Models

NK cells are effector innate lymphoid cells (ILCs) that do not require antigen-specific priming. NK cells are not only killer cells that help to suppress tumors, but also are involved in the generation and maintenance of adaptive immune responses.  The process of antibody-dependent cell-mediated cytotoxicity (ADCC) makes use of innate immune cells which provide antitumor …Read More >

Resource Type: Latest Science, Presentation
Resource Topic: Immunology, Oncology, Tumor Models

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!